KDEL-grafted chondroitin sulfate CPD/siBcl-2/CK
Sequence: KDEL
| Experiment Id | EXP002474 |
|---|---|
| Paper | Dual Strategies Based on Golgi Apparatus/Endoplasmic Reticulum Targeting and Anchoring for High-Effi |
| Peptide | KDEL-grafted chondroitin sulfate CPD/siBcl-2/CK |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | KDEL grafting ratio on chondroitin sulfate approximately 11% |
| Rna Concentration | In vivo siRNA dose 1 mg/kg where applicable; exact in vitro siRNA concentration not fully specified for luciferase assay |
| Mixing Ratio | CPD/siRNA/CK prepared by CPD/siRNA complexation followed by coating with KDEL-grafted chondroitin sulfate; C/Gu ratios screened, same strategy as CPD/siRNA/CS |
| Formulation Format | polymer/polysaccharide nanocomplex |
| Formulation Components | Cell-penetrating poly(disulfide) (CPD), siRNA, KDEL-grafted chondroitin sulfate (CK); CK provides CD44-associated targeting/Golgi transport and KDEL-mediated ER-directed sorting |
| Size Nm | 167.20 |
| Zeta Mv | -13.60 |
| Model Scope | in_vitro |
| Model Type | in vitro reporter RNAi assay |
| Cell Lines Or Primary Cells | B16F10-Luc melanoma cells |
| Animal Model | |
| Administration Route | |
| Output Type | in vitro target-gene knockdown |
| Output Value | CPD/siLuc/CK reduced luciferase expression to 32.7 ± 2.0%, lower than CPD/siLuc/CS at 46.9 ± 1.3% |
| Output Units | |
| Output Notes | KDEL-directed sorting increased cellular retention and RNAi efficiency versus CS-coated comparator; uptake and ER/Golgi routing were directly evaluated by fluorescence microscopy/flow cytometry. |
| Toxicity Notes | Good cytocompatibility of nanocomplexes was reported in normal cells/HUVEC in supplementary data. |
| Curation Notes |